ST Tiansheng announced that its wholly-owned subsidiary, Hubei Tiansheng Pharmaceutical Co., Ltd., recently received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration, and the product “Vitamin B6 Injection” passed the generic drug consistency evaluation. The drug specification is 1 ml: 0.1 g, and the approval number is valid until March 28, 2027. Clinically, it is used for prevention and treatment of vitamin B6 deficiency, etc. The evaluation this time has accumulated experience for the company to carry out related work in the future, but drug sales are affected by policies and the market environment, and there is uncertainty.

ST Tiansheng announced that its wholly-owned subsidiary, Hubei Tiansheng Pharmaceutical Co., Ltd., recently received the “Drug Supplement Application Approval Notice” approved and issued by the State Drug Administration, and the product “Vitamin B6 Injection” passed the generic drug consistency evaluation. The drug specification is 1 ml: 0.1 g, and the approval number is valid until March 28, 2027. Clinically, it is used for prevention and treatment of vitamin B6 deficiency, etc. The evaluation this time has accumulated experience for the company to carry out related work in the future, but drug sales are affected by policies and the market environment, and there is uncertainty.